利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.02 秒)

    Sheet roll and sheet-like coupling member
    1.
    发明申请
    Sheet roll and sheet-like coupling member 有权
    板卷和片状联接件

    公开(公告)号：US20120015132A1

    公开(公告)日：2012-01-19

    申请号：US13182613

    申请日：2011-07-14

    申请人： Yoshinori HASEGAWA ,  Hiroshi ADACHI ,  Hiroki MORI ,  Kaoru MITSUGI ,  Naohiro IKAI

    发明人： Yoshinori HASEGAWA ,  Hiroshi ADACHI ,  Hiroki MORI ,  Kaoru MITSUGI ,  Naohiro IKAI

    IPC分类号： B32B3/00 ,  F16B5/00

    CPC分类号： B65H21/00 ,  B65H2301/46325 ,  Y10T403/76 ,  Y10T428/19 ,  Y10T428/192 ,  Y10T428/197

    摘要： A sheet roll (1) is manufactured by placing a sheet-like coupling member (3) on end portions of a plurality of glass films (g) so as to span therebetween, coupling the end portions of the glass films (g) together, and rolling the coupled plurality of glass films (g). The sheet-like coupling member (3) used in the sheet roll (1) includes wide width portions (4) for forming wide joint portions joined to the glass films (g) at each of both end portions thereof in a rolling direction, and a necked portion (5), which is narrower than the wide width portions (4) and is formed at a middle portion thereof in the rolling direction.

    摘要翻译： 通过在多个玻璃膜（g）的端部放置片状连结部件（3），使其间夹着玻璃膜（g）的一部分，将玻璃膜（g）的端部 并滚动耦合的多个玻璃膜（g）。 用于片材卷（1）中的片状连接件（3）包括用于在轧制方向的两个端部中形成与玻璃膜（g）接合的宽接合部分的宽宽度部分（4），以及 颈部（5），其比宽幅部（4）窄，并且形成在轧制方向的中间部。

    METHOD OF ESTIMATING THE RISK OF EXPRESSION OF ADVERSE DRUG REACTION CAUSED BY THE ADMINISTRATION OF A COMPOUND, WHICH IS EITHER METABOLIZED PER SE BY UGT1A1 ENZYME OR WHOSE METABOLIC INTERMEDIATE IS METABOLIZED BY THE ENZYME
    2.
    发明申请
    METHOD OF ESTIMATING THE RISK OF EXPRESSION OF ADVERSE DRUG REACTION CAUSED BY THE ADMINISTRATION OF A COMPOUND, WHICH IS EITHER METABOLIZED PER SE BY UGT1A1 ENZYME OR WHOSE METABOLIC INTERMEDIATE IS METABOLIZED BY THE ENZYME 审中-公开
    估计由化合物的施用引起的不良药物反应的风险的方法，每种化合物由UGT1A1酶代谢，或代谢中间体被酶代谢

    公开(公告)号：US20110151474A1

    公开(公告)日：2011-06-23

    申请号：US13026719

    申请日：2011-02-14

    申请人： Yoshinori HASEGAWA ,  Yu-uichi ANDO ,  Kaoru SHIMOKATA

    发明人： Yoshinori HASEGAWA ,  Yu-uichi ANDO ,  Kaoru SHIMOKATA

    IPC分类号： C12Q1/68

    CPC分类号： C12N9/1051 ,  C12Q1/6876 ,  C12Q2600/156

    摘要： A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan.

    摘要翻译： 评价由伊立替康的给药引起的药物不良反应的风险的评价方法以及减少由伊立替康给药引起的不良药物反应的方法。 基于外显子1的单核苷酸多态性，基于UGT1基因的启动子区域的TA重复序列的重复数和两种类型的多态性（211-和686位的碱基）的差异的多态性 被分析。 根据分析资料，估计伊立替康的施用引起药物不良反应的风险。 此外，根据不利的drub反应的表达风险，为个体患者设计了伊立替康的给药剂量，从而减少了施用伊立替康引起的不良药物反应。